Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache

Next Previous
X
Search
Trial Profile

Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Cluster headache
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLEVIATE
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 13 Jun 2024 According to Lundbeck media release, company announced data presentations of this trial at the 66th Annual Scientific Meeting of the American Headache Society (AHS) taking place in San Diego, Calif., June 13-16, 2024
    • 10 Mar 2024 This trial has been Discontinued in Portugal, according to European Clinical Trials Database record.
    • 06 Feb 2024 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top